-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to improve the diagnosis and treatment of Waldenstrom's macroglobulinemia (WM) by clinicians in China, standardize the WM treatment plan, and strengthen the efficacy evaluation and follow-up of WM, the China WM Working Group Quarterly Meeting and International WM Symposium will be held on September 24, 2021 Successfully held online
.
The theme of this conference is "Primary Dialogue, One Million Way Forward", bringing together well-known experts at home and abroad, focusing on the frontiers of WM clinical practice, and presenting a gluttonous academic feast
.
Summit Dialogue: Chinese and foreign experts talk about the new progress of WM genome research.
After the chairman of the conference, Professor Hou Jian from Renji Hospital, Shanghai Jiaotong University School of Medicine gave a wonderful speech.
Professor Qiu Lugui from the Hospital of Hematology, Chinese Academy of Medical Sciences and the Cancer Institute of Harvard Medical School, USA Professor Steven Treon of Fahrenheit Giant Ball Center discussed the current status and progress of WM diagnosis and treatment
.
Professor Steven Treon made a wonderful sharing based on the application of genomics to treat WM.
He pointed out that the combination of ibrutinib and rituximab has a significant effect and is based on different genotypes of patients, even for patients with MYD88 and CXCR4 double mutations.
You can also get a good effect from the combination therapy
.
Professor Steven Treon believes that Venecla is also a very effective drug for the treatment of WM.
The application of Ibrutinib combined with Venecla may bring better efficacy to patients with double mutations or double non-mutations of MYD88 and CXCR4
.
Keep improving: Open a new era of precision treatment with long-term long-term safety and rapid relief.
In order to promote the arrival of a new era of precision treatment for Chinese patients, under the chairmanship of the chairman of the conference, Professor Li Jian from Peking Union Medical College Hospital, Professor Wang Li shared the current domestic and foreign WM diagnosis and treatment Progress, detailed descriptions of WM disease manifestations and treatment indications, a review of WM epidemiology and treatment models at home and abroad, and new advances in WM clinical research based on BTK inhibitors, emphasizing that “Ibrutinib is Guidelines such as "Preferential treatment options"
.
Professor Wang Li pointed out that the current application of BTKi drugs has brought more changes to the treatment model of WM: China's real-world data show that the most commonly used single drug is chlorambucil, and the emergence of ibrutinib is also accelerating In response to changes in the treatment model, because Ibrutinib works faster, patients can obtain partial remission (PR) or more effects earlier; data from Changzheng Hospital also shows the same results; real-world research conducted by the Mayo Clinic The data also show that Ibrutinib monotherapy has a significant effect on WM
.
At the same time, Professor Wang Li expressed the hope that ongoing clinical studies including Ibrutinib combined with ixazomib treatment, and daratumomab combined with Venecla, etc.
will enable Chinese patients to get better treatment.
Effect
.
In the subsequent discussion session, Professor Zhan Rong emphasized that ibrutinib entered the medical insurance this year to improve the accessibility of patients, so that most of the confirmed patients can receive the treatment of ibrutinib
.
At the same time, Professor Zhan Rong said that molecular diagnosis is very important for the precise treatment of diseases, but the hospital is still unable to complete the CXCR4 test, and hopes that the working group can develop a more complete and standardized diagnosis framework in the future
.
Regarding the problem of distinguishing the main phenotypes of lymphoplasmacytoma and marginal zone lymphoma proposed by Professor Wei Yongqiang, Professor Li Jian said that if the patient is MYD88 positive, it can be directly judged as WM.
If MYD88 is negative and the spleen or lymph node pathological results are abnormal, It is recommended to classify cases of lymphoma in the marginal zone, and it can also be diagnosed in combination with clinical manifestations.
For example, patients with particularly high IgM levels are classified as WM, and low IgM levels are classified as marginal zone lymphomas.
Professor Yi Shuhua suggested, yes.
Accurate sequencing is performed on the Janssen platform for identification.
This platform has high accuracy and satisfactory results
.
Moving forward on the Yilu Road: Step into the era of "no chemotherapy" with precise targeting and rapid remission of safe treatment.
Next, under the chairmanship of the conference chairperson, Professor Du Juan from Shanghai Changzheng Hospital, Professor Yi Shuhua learned that traditional immunochemotherapy could not achieve precise and safe treatment of WM , Ibrutinib precise targeting, it is a BTK inhibitor unanimously recommended by domestic and foreign guidelines, and several other aspects shared the "no chemotherapy" era of WM created by Ibrutinib, and interpreted the specific data of Ibrutinib in the treatment of WM.
Emphasizes the relative advantages of ibrutinib in WM treatment
.
During the discussion session, Professor Qiu Hongxia raised the issue of whether to stop the drug, maintain the treatment time and whether to recommend intermittent discontinuation when the symptoms improve after treatment.
Professor Yi Shuhua said that patients receiving ibrutinib monotherapy should not be tolerated Or if the disease progresses, long-term medication is recommended.
If the disease progresses, cross-treatment is recommended.
Intermittent administration is not recommended, as it is easy to induce drug resistance
.
Regarding how to safely stop the drug, the working group was discussing before the launch of Ibrutinib, and is currently observing whether the BR regimen plus 3 to 4 courses of Ibrutinib can improve the efficacy
.
For Professor Bao Jing’s IgA type lymphoplasmacytic lymphoma with 0.
7% MYD88 mutation, can Ibrutinib be added, or Ibrutinib can be used for single-drug therapy, or Ibrahimovic after BR regimen treatment? The maintenance treatment of tinib, and whether non-WM such as ibrutinib can be reimbursed according to Fahrenheit’s indications, Professor Yi Shuhua said that if patients with IgA type lymphoplasmacytic lymphoma have MYD88 hypermutation, ibruti can be used.
Nymph is treated as a single agent, and non-WM lymphoplasmacytic lymphoma is still treated according to the treatment model of lymphoplasmacytic lymphoma
.
Stones from Other Mountains: Standardized Diagnosis and Treatment Sharing by CwWM Working Group Members In addition, under the auspices of Professor Cai Zhen from the First Affiliated Hospital of Zhejiang University School of Medicine and Professor Jiang Zhongxing from the First Affiliated Hospital of Zhengzhou University, Yang Professor Yang and Professor Zhang Yinyin from the First Affiliated Hospital of Zhengzhou University respectively shared their WM diagnosis and treatment process and the incidence of cases and treatment cases.
Professor Luo Jun from the First Affiliated Hospital of Guangxi Medical University and Professor Xue Hua from the Affiliated Hospital of Hebei University conducted the case.
Reviews
.
Concluding Remarks Participating experts conducted a heated discussion on the hotspots and difficult issues of WM diagnosis and treatment and shared wonderful cases.
Professor Yi Shuhua from the Hospital of Hematology, Chinese Academy of Medical Sciences concluded that the testing platform is currently being further built and improved with the support of Xi'an Janssen.
Following the first discovery of MYD88 and CXCR4 gene mutations, a series of targeted drugs have now been developed, especially the clinical application of CXCR4 targeted drugs, which is of great significance.
However, the frequency of MYD88 and CXCR4 gene mutations in the Chinese patient population remains to be explored , I hope that through the joint efforts of everyone in the future, we will deepen our understanding of WM, so as to further improve the level of WM diagnosis and treatment
.
Poke "read the original text", we make progress together
.
The theme of this conference is "Primary Dialogue, One Million Way Forward", bringing together well-known experts at home and abroad, focusing on the frontiers of WM clinical practice, and presenting a gluttonous academic feast
.
Summit Dialogue: Chinese and foreign experts talk about the new progress of WM genome research.
After the chairman of the conference, Professor Hou Jian from Renji Hospital, Shanghai Jiaotong University School of Medicine gave a wonderful speech.
Professor Qiu Lugui from the Hospital of Hematology, Chinese Academy of Medical Sciences and the Cancer Institute of Harvard Medical School, USA Professor Steven Treon of Fahrenheit Giant Ball Center discussed the current status and progress of WM diagnosis and treatment
.
Professor Steven Treon made a wonderful sharing based on the application of genomics to treat WM.
He pointed out that the combination of ibrutinib and rituximab has a significant effect and is based on different genotypes of patients, even for patients with MYD88 and CXCR4 double mutations.
You can also get a good effect from the combination therapy
.
Professor Steven Treon believes that Venecla is also a very effective drug for the treatment of WM.
The application of Ibrutinib combined with Venecla may bring better efficacy to patients with double mutations or double non-mutations of MYD88 and CXCR4
.
Keep improving: Open a new era of precision treatment with long-term long-term safety and rapid relief.
In order to promote the arrival of a new era of precision treatment for Chinese patients, under the chairmanship of the chairman of the conference, Professor Li Jian from Peking Union Medical College Hospital, Professor Wang Li shared the current domestic and foreign WM diagnosis and treatment Progress, detailed descriptions of WM disease manifestations and treatment indications, a review of WM epidemiology and treatment models at home and abroad, and new advances in WM clinical research based on BTK inhibitors, emphasizing that “Ibrutinib is Guidelines such as "Preferential treatment options"
.
Professor Wang Li pointed out that the current application of BTKi drugs has brought more changes to the treatment model of WM: China's real-world data show that the most commonly used single drug is chlorambucil, and the emergence of ibrutinib is also accelerating In response to changes in the treatment model, because Ibrutinib works faster, patients can obtain partial remission (PR) or more effects earlier; data from Changzheng Hospital also shows the same results; real-world research conducted by the Mayo Clinic The data also show that Ibrutinib monotherapy has a significant effect on WM
.
At the same time, Professor Wang Li expressed the hope that ongoing clinical studies including Ibrutinib combined with ixazomib treatment, and daratumomab combined with Venecla, etc.
will enable Chinese patients to get better treatment.
Effect
.
In the subsequent discussion session, Professor Zhan Rong emphasized that ibrutinib entered the medical insurance this year to improve the accessibility of patients, so that most of the confirmed patients can receive the treatment of ibrutinib
.
At the same time, Professor Zhan Rong said that molecular diagnosis is very important for the precise treatment of diseases, but the hospital is still unable to complete the CXCR4 test, and hopes that the working group can develop a more complete and standardized diagnosis framework in the future
.
Regarding the problem of distinguishing the main phenotypes of lymphoplasmacytoma and marginal zone lymphoma proposed by Professor Wei Yongqiang, Professor Li Jian said that if the patient is MYD88 positive, it can be directly judged as WM.
If MYD88 is negative and the spleen or lymph node pathological results are abnormal, It is recommended to classify cases of lymphoma in the marginal zone, and it can also be diagnosed in combination with clinical manifestations.
For example, patients with particularly high IgM levels are classified as WM, and low IgM levels are classified as marginal zone lymphomas.
Professor Yi Shuhua suggested, yes.
Accurate sequencing is performed on the Janssen platform for identification.
This platform has high accuracy and satisfactory results
.
Moving forward on the Yilu Road: Step into the era of "no chemotherapy" with precise targeting and rapid remission of safe treatment.
Next, under the chairmanship of the conference chairperson, Professor Du Juan from Shanghai Changzheng Hospital, Professor Yi Shuhua learned that traditional immunochemotherapy could not achieve precise and safe treatment of WM , Ibrutinib precise targeting, it is a BTK inhibitor unanimously recommended by domestic and foreign guidelines, and several other aspects shared the "no chemotherapy" era of WM created by Ibrutinib, and interpreted the specific data of Ibrutinib in the treatment of WM.
Emphasizes the relative advantages of ibrutinib in WM treatment
.
During the discussion session, Professor Qiu Hongxia raised the issue of whether to stop the drug, maintain the treatment time and whether to recommend intermittent discontinuation when the symptoms improve after treatment.
Professor Yi Shuhua said that patients receiving ibrutinib monotherapy should not be tolerated Or if the disease progresses, long-term medication is recommended.
If the disease progresses, cross-treatment is recommended.
Intermittent administration is not recommended, as it is easy to induce drug resistance
.
Regarding how to safely stop the drug, the working group was discussing before the launch of Ibrutinib, and is currently observing whether the BR regimen plus 3 to 4 courses of Ibrutinib can improve the efficacy
.
For Professor Bao Jing’s IgA type lymphoplasmacytic lymphoma with 0.
7% MYD88 mutation, can Ibrutinib be added, or Ibrutinib can be used for single-drug therapy, or Ibrahimovic after BR regimen treatment? The maintenance treatment of tinib, and whether non-WM such as ibrutinib can be reimbursed according to Fahrenheit’s indications, Professor Yi Shuhua said that if patients with IgA type lymphoplasmacytic lymphoma have MYD88 hypermutation, ibruti can be used.
Nymph is treated as a single agent, and non-WM lymphoplasmacytic lymphoma is still treated according to the treatment model of lymphoplasmacytic lymphoma
.
Stones from Other Mountains: Standardized Diagnosis and Treatment Sharing by CwWM Working Group Members In addition, under the auspices of Professor Cai Zhen from the First Affiliated Hospital of Zhejiang University School of Medicine and Professor Jiang Zhongxing from the First Affiliated Hospital of Zhengzhou University, Yang Professor Yang and Professor Zhang Yinyin from the First Affiliated Hospital of Zhengzhou University respectively shared their WM diagnosis and treatment process and the incidence of cases and treatment cases.
Professor Luo Jun from the First Affiliated Hospital of Guangxi Medical University and Professor Xue Hua from the Affiliated Hospital of Hebei University conducted the case.
Reviews
.
Concluding Remarks Participating experts conducted a heated discussion on the hotspots and difficult issues of WM diagnosis and treatment and shared wonderful cases.
Professor Yi Shuhua from the Hospital of Hematology, Chinese Academy of Medical Sciences concluded that the testing platform is currently being further built and improved with the support of Xi'an Janssen.
Following the first discovery of MYD88 and CXCR4 gene mutations, a series of targeted drugs have now been developed, especially the clinical application of CXCR4 targeted drugs, which is of great significance.
However, the frequency of MYD88 and CXCR4 gene mutations in the Chinese patient population remains to be explored , I hope that through the joint efforts of everyone in the future, we will deepen our understanding of WM, so as to further improve the level of WM diagnosis and treatment
.
Poke "read the original text", we make progress together
